Recurrent Esophageal Carcinoma (DBCOND0047841)
Identifiers
- Synonyms
- Oesophageal carcinoma recurrent / Recurrent Oesophageal Carcinoma / Oesophageal carcinoma site unspecified recurrent / Esophageal carcinoma site unspecified recurrent / Esophageal carcinoma recurrent
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - ABSK-091
- Adavosertib
- Afatinib
- Binimetinib
- Capivasertib
- Copanlisib
- Crizotinib
- Dabrafenib
- Dasatinib
- Defactinib
- Erdafitinib
- GSK-2636771
- Ipatasertib
- Larotrectinib
- Methane
- Nivolumab
- Osimertinib
- Palbociclib
- Pertuzumab
- Relatlimab
- Sapanisertib
- Sulfate ion
- Sunitinib
- Taselisib
- Trametinib
- Trastuzumab
- Trastuzumab emtansine
- Tyrosine
- Ulixertinib
- Vismodegib
screening 2 active_not_recruiting NCT03008278 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery treatment 1 / 2 active_not_recruiting NCT03196232 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer treatment 2 completed NCT01522820 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT01142388 Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer treatment 2 active_not_recruiting